The Perfect Storm for Brilacidin
We are 20+ months into the worst pandemic in over 100 years. There have been an estimated 219M CV19 cases and this virus has taken an estimated 4.55M lives. In addition to the loss of human lives, the economic and social impact caused by CV19 has been tremendous.
The CV19 virus continues to mutate and new strains and variants are becoming more contagious, more severe and more challenging to contain and treat. Numerous posts have correctly stated that an effective CV19 therapeutic is needed in addition to vaccines to combat this epidemic. The following is an attempt to explain this statement and how Brilacidin is uniquely positioned to become a major weapon against this pandemic and future viruses and/or bioweapons.
The primary investment that has been made to combat this pandemic has been the development of CV19 vaccines. To understand the benefits and limitations of a CV19 vaccination, it is important to understand the difference between “Perfect” vaccines and “Imperfect or Leaky” vaccines“. Perfect vaccines are so-named because they mimic the perfect immunity that humans naturally develop after having certain childhood diseases. Perfect vaccines prevent the vaccinated person from being sickened by the virus or disease and also prevent the patient from transmitting the virus to others. Examples of Perfect vaccines include many childhood vaccinations such as polio, measles, rubella, mumps and smallpox. Herd Immunity can be achieved in a Perfect vaccinated world which is why as a civilization we no longer have to deal with polio and other Perfect vaccinated diseases
Every vaccine for enveloped viruses (flu shots, CV19) that have been developed to date are “Imperfect” or “Leaky” vaccines. This means that they are effective in reducing the impact of the virus symptoms but the vaccinated individual can still potentially carry and transmit the virus. A Leaky virus is an important short term weapon against the pandemic as it reduces the symptoms of the virus and saves lives in treating the most vulnerable portion of the population. The down side of a Leaky vaccine is that it cannot on its own provide Herd Immunity (HI). The negative long term results of using a Leaky vaccination on the masses is that the virus needs hosts to survive and it mutates into stronger resistance and in some cases more severe strains. To be very clear, I am not anti-vax. I personally chose to get the J&J vaccine as I felt the risk/reward for me personally favored this decision.
There is a great need for effective therapeutics to treat infected individuals as a critical component to combating the pandemic. There are 2 major problems with existing or repurposed therapeutics that are currently available to treat CV19. Firstly, none of the available therapeutics kill the CV19 virus. Their method of action slows the reproduction and spread of the virus and therefore reduces the overall viral load but does not completely disable or kill the virus. Secondly, the existing repurposed antivirals must be used very early in the disease process and they lose their effectiveness the longer the patient has been sick. In most cases the viral load in moderate/severe CV19 patients is at a point where halting viral replication is too late to help the patient. The biggest threat to severe patients is the human body’s immune system going into an inflammatory response and potentially cascading into a cytokine storm as it attempts to fight the virus but gets thrown into overdrive. At this stage the immune response attacks organs and the human body starts to shut down causing the need in many cases for intubation and in far too many cases death. Note that Pete’s post #70346 references a recent study in Europe for hospitalized CV19 patients where remdesivir was used in combination with an existing European standard of care (SOC) and was proven to have no benefit. This should come as little surprise as remdesivir has the same limitations as all other repurposed antivirals as mentioned above. This study basically added one repurposed antiviral on top of another with no improvements. Interesting to note that remdesivir produced $2.8B in revenue last year as a mostly ineffective drug. It was initially approved because it shortened hospital stays but there was no antiviral at that time used as the placebo SOC to compare it to.
Brilacidin is a new class of drug as a defensin-mimetic with anti-inflammatory/antibiotic/antiviral properties. It has been proven to block viral integrity and entry, essentially killing the CV19 virus. In Regional Biocontainment Lab (RBL) studies on human tissue it was determined to have a 426 Selectivity Index, demonstrating both effectiveness and safety. Brilacidin’s unique anti-inflammatory and modulation properties will help prevent cytokine storm related issues. Brilacidin could also prove to be less prone to resistance developing due to viral mutations, which is a major weakness of other antivirals. If the upcoming human trial results replicate these superior lab results, Brilacidin will become the new Gold Standard antiviral and will become a valuable weapon against the fight against CV19 and future viruses and pandemics.
CV19 is a worldwide catastrophic emergency and no single entity (whether it be an individual Big Pharmaceutical (BP) or even an individual country) will be able to hold it back. The worldwide demand for an effective therapeutic is currently unmet. Leo wisely did a multinational study that included patients from both the U.S. and Russia. Different SOC’s were used which should prove Brilacidin’s superiority over ALL existing antiviral SOCs. IMO Brilacidin will be initially deployed as both a combination and stand-alone therapeutic, which could vary by country. The demand for a Broad Spectrum antiviral is huge and IMO the U.S. DoD could very well be one of IPIX’s first customers. The CV19 antiviral market alone is huge as proven by the $2.8B remdesivir revenue last year. IMO the follow-on product will be an inhaler and/or depo delivery so that Brilacidin could be easily used at the earliest sign of symptoms from any of the flu, CV19 or other virus or bacterial infections. The market opportunity for this general use Broad Spectrum antiviral/antibiotic would be enormous.
https://www.geertvandenbossche.org/post/the-last-post
https://pubmed.ncbi.nlm.nih.gov/24895500/
https://www.reuters.com/world/uk/england-says...021-08-06/
http://www.ipharminc.com/press-release/2021/7/22/Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting
We are 20+ months into the worst pandemic in over 100 years. There have been an estimated 219M CV19 cases and this virus has taken an estimated 4.55M lives. In addition to the loss of human lives, the economic and social impact caused by CV19 has been tremendous.
The CV19 virus continues to mutate and new strains and variants are becoming more contagious, more severe and more challenging to contain and treat. Numerous posts have correctly stated that an effective CV19 therapeutic is needed in addition to vaccines to combat this epidemic. The following is an attempt to explain this statement and how Brilacidin is uniquely positioned to become a major weapon against this pandemic and future viruses and/or bioweapons.
The primary investment that has been made to combat this pandemic has been the development of CV19 vaccines. To understand the benefits and limitations of a CV19 vaccination, it is important to understand the difference between “Perfect” vaccines and “Imperfect or Leaky” vaccines“. Perfect vaccines are so-named because they mimic the perfect immunity that humans naturally develop after having certain childhood diseases. Perfect vaccines prevent the vaccinated person from being sickened by the virus or disease and also prevent the patient from transmitting the virus to others. Examples of Perfect vaccines include many childhood vaccinations such as polio, measles, rubella, mumps and smallpox. Herd Immunity can be achieved in a Perfect vaccinated world which is why as a civilization we no longer have to deal with polio and other Perfect vaccinated diseases
Every vaccine for enveloped viruses (flu shots, CV19) that have been developed to date are “Imperfect” or “Leaky” vaccines. This means that they are effective in reducing the impact of the virus symptoms but the vaccinated individual can still potentially carry and transmit the virus. A Leaky virus is an important short term weapon against the pandemic as it reduces the symptoms of the virus and saves lives in treating the most vulnerable portion of the population. The down side of a Leaky vaccine is that it cannot on its own provide Herd Immunity (HI). The negative long term results of using a Leaky vaccination on the masses is that the virus needs hosts to survive and it mutates into stronger resistance and in some cases more severe strains. To be very clear, I am not anti-vax. I personally chose to get the J&J vaccine as I felt the risk/reward for me personally favored this decision.
There is a great need for effective therapeutics to treat infected individuals as a critical component to combating the pandemic. There are 2 major problems with existing or repurposed therapeutics that are currently available to treat CV19. Firstly, none of the available therapeutics kill the CV19 virus. Their method of action slows the reproduction and spread of the virus and therefore reduces the overall viral load but does not completely disable or kill the virus. Secondly, the existing repurposed antivirals must be used very early in the disease process and they lose their effectiveness the longer the patient has been sick. In most cases the viral load in moderate/severe CV19 patients is at a point where halting viral replication is too late to help the patient. The biggest threat to severe patients is the human body’s immune system going into an inflammatory response and potentially cascading into a cytokine storm as it attempts to fight the virus but gets thrown into overdrive. At this stage the immune response attacks organs and the human body starts to shut down causing the need in many cases for intubation and in far too many cases death. Note that Pete’s post #70346 references a recent study in Europe for hospitalized CV19 patients where remdesivir was used in combination with an existing European standard of care (SOC) and was proven to have no benefit. This should come as little surprise as remdesivir has the same limitations as all other repurposed antivirals as mentioned above. This study basically added one repurposed antiviral on top of another with no improvements. Interesting to note that remdesivir produced $2.8B in revenue last year as a mostly ineffective drug. It was initially approved because it shortened hospital stays but there was no antiviral at that time used as the placebo SOC to compare it to.
Brilacidin is a new class of drug as a defensin-mimetic with anti-inflammatory/antibiotic/antiviral properties. It has been proven to block viral integrity and entry, essentially killing the CV19 virus. In Regional Biocontainment Lab (RBL) studies on human tissue it was determined to have a 426 Selectivity Index, demonstrating both effectiveness and safety. Brilacidin’s unique anti-inflammatory and modulation properties will help prevent cytokine storm related issues. Brilacidin could also prove to be less prone to resistance developing due to viral mutations, which is a major weakness of other antivirals. If the upcoming human trial results replicate these superior lab results, Brilacidin will become the new Gold Standard antiviral and will become a valuable weapon against the fight against CV19 and future viruses and pandemics.
CV19 is a worldwide catastrophic emergency and no single entity (whether it be an individual Big Pharmaceutical (BP) or even an individual country) will be able to hold it back. The worldwide demand for an effective therapeutic is currently unmet. Leo wisely did a multinational study that included patients from both the U.S. and Russia. Different SOC’s were used which should prove Brilacidin’s superiority over ALL existing antiviral SOCs. IMO Brilacidin will be initially deployed as both a combination and stand-alone therapeutic, which could vary by country. The demand for a Broad Spectrum antiviral is huge and IMO the U.S. DoD could very well be one of IPIX’s first customers. The CV19 antiviral market alone is huge as proven by the $2.8B remdesivir revenue last year. IMO the follow-on product will be an inhaler and/or depo delivery so that Brilacidin could be easily used at the earliest sign of symptoms from any of the flu, CV19 or other virus or bacterial infections. The market opportunity for this general use Broad Spectrum antiviral/antibiotic would be enormous.
https://www.geertvandenbossche.org/post/the-last-post
https://pubmed.ncbi.nlm.nih.gov/24895500/
https://www.reuters.com/world/uk/england-says...021-08-06/
http://www.ipharminc.com/press-release/2021/7/22/Innovation Pharmaceuticals Announces New In Vitro Data Supporting Brilacidin’s Broad-Spectrum Antiviral Potential Presented at the American Society of Virology’s Annual Meeting
19
2
